Dispute intensifies as both parties write to district court hours after Court of Appeals order | MSN maintains that the ...

The affirmative regulatory decision is the third for Novartis’s Fabhalta, building up the drug’s pipeline-in-a-product potential. But competition looms from a rival drug taking a similar approach.

Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory ...

Pharming has agreed a deal to sell a recently awarded priority review voucher (PRV) to Novartis for around $21 million - well below the market rate. The price of PRVs, which can be used to shorten ...

The FDA has granted Novartis’ Zykadia a speedy review in first-line use in certain lung cancer patients, setting up a showdown with Roche’s rival, Alecensa. The US regulator gave Zykadia ...

Novartis’ oral Fabhalta (iptacopan) has been approved by the US Food and Drug Administration (FDA) as the first treatment for ...

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...

To receive full access to Campaign's content including: Unrestricted access to all The Information and The Knowledge content Access to Campaign's in-depth features and coveted reports including ...

(RTTNews) - Novartis AG (NVS) announced that the U.S ... Opinion in C3G by the European Medicines Agency (EMA). Regulatory reviews for this indication are ongoing in China and Japan.

Basel: Novartis has announced that the U.S. Food and Drug Administration (FDA) has approved oral Fabhalta (iptacopan) for the ...

Novartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication. The regulatory body approved ...